Articles

Altavant Sciences Articles

August 4, 2020MarketScreenerNews

Altavant Sciences Presentation at ATS 2020 Confirms Minimal Brain Exposure of Peripherally Acting Serotonin Modulator, Rodatristat Ethyl, in Clinical Development for PAH

(marketscreener.com) Cary, N.C. and Basel, Switzerland, Aug. 05, 2020 -- Altavant Sciences, a clinica... See more »
March 2, 2020FierceBiotechNews

Altavant nabs Boehringer, Gilead alum as new CMO

While no longer a member of Vivek Ramaswamy's Roivant umbrella group, his former Vant company is stil... See more »
January 10, 2020Global Legal ChronicleNews

Altavant Sciences' Acquisition Of Onspira Therapeutics

Hogan Lovells advised Altavant Sciences in its acquisition of Onspira Therapeutics. This acquisition ... See more »
January 8, 2020The Business Journals: Raleigh/DurhamNews

Cary drugmaker makes first acquisition with new financial backing

A Triangle drugmaker starting the year with a fresh financial backer has made an acquisition of its o... See more »
January 8, 2020The Business Journals: PhiladelphiaNews

Wayne biopharmaceutical company sold to North Carolina drug developer

Onspira Therapeutics, a Wayne-based biopharmaceutical company developing treatments for rare pulmonar... See more »
October 22, 2019PR NewswirePress Release

Altavant Sciences Presents Data at CHEST 2019 Supporting Once-Daily Dosing of Rodatristat Ethyl for the Treatment of Pulmonary Arterial Hypertension

CARY, N.C. and BASEL, Switzerland, Oct. 22, 2019 /PRNewswire/ -- Altavant Sciences, a clinical-stage ... See more »
October 1, 2019PR NewswirePress Release

Altavant Sciences Presents Data at ERS International Congress 2019 Demonstrating Strong Safety and Tolerability Profile of Rodatristat Ethyl

CARY, N.C. and BASEL, Switzerland, Oct. 1, 2019 /PRNewswire/ -- Altavant Sciences, a clinical-stage b... See more »
September 5, 2019PR NewswirePress Release

Altavant Sciences Presents Patient-Centric Approach to Drug Development at PHA's Annual PHPN Symposium

CARY, N.C. and BASEL, Switzerland, Sept. 5, 2019 /PRNewswire/ -- Altavant Sciences, a clinical-stage ... See more »
August 5, 2019PR NewswirePress Release

Altavant Sciences Initiates Phase 2a Study of Rodatristat Ethyl in Pulmonary Arterial Hypertension

CARY, N.C. and BASEL, Switzerland, Aug. 5, 2019 /PRNewswire/ -- Altavant Sciences, a clinical-stage b... See more »
August 5, 2019Drug Development TechnologyNews

Altavant doses first patient in ELEVATE 1 trial of PAH drug

Altavant Sciences has dosed the first patient in the ELEVATE 1 trial of its lead candidate rodatrista... See more »
May 9, 2019PR NewswirePress Release

Altavant Sciences to Provide Corporate and Clinical Update at 2019 Respiratory Innovation Summit

CARY, N.C. and BASEL, Switzerland, May 9, 2019 /PRNewswire/ -- Altavant Sciences, a company in the Ro... See more »
January 31, 2019PR NewswirePress Release

Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at PVRI World Congress

BASEL, Switzerland and DURHAM, N.C., Jan. 31, 2019 /PRNewswire/ -- Altavant Sciences, a company in th... See more »
January 3, 2019biocenturyNews

Altavant Sciences subsidiary hired Lyn Baranowski as COO

Altavant Sciences subsidiary hired Lyn Baranowski as COO... See more »
Loading interface...
Loading interface...
Loading interface...